Skip to main content
Premium Trial:

Request an Annual Quote

Expression Analysis to Genotype Samples for SAEC's Liver Toxicity Project

NEW YORK (GenomeWeb News) – The Serious Adverse Events Consortium has selected Expression Analysis as the exclusive provider of genotyping services for its first research project, the genomic services firm said yesterday.
 
The first project will focus on liver toxicity using samples provided by DILIGEN and EUDRAGENE, two European clinical research networks. Expression Analysis said that it will use Illumina's Human 1M DNA Analysis BeadChip to perform the genotyping on these samples.
 
The SAEC, launched last month, is a collaboration between the US Food and Drug Administration, several pharmaceutical companies, and academic research groups to identify genetic biomarkers that may predict which individuals are at risk for drug-related adverse events.  
 
Arthur Holden, chairman of the SAEC, said in a statement that the consortium’s scientific management committee “independently evaluated many competing proposals and selected Expression Analysis based on its extensive ‘quality system’ and service track record.”

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.